OBJECTIVE: To assess which baseline clinical and MRI measures influence whole-brain atrophy rates, measured from serial MR imaging. METHODS: We recruited 65 patients with Alzheimer disease (mean +/- SD age 70 +/- 8 y, 58% women, Mini-Mental State Examination [MMSE] 22 +/- 5), scanned with an average interval of 1.7 +/- 0.6 years. Whole-brain atrophy rates were used as outcome measure. Baseline normalized brain volume, hippocampal volume, and whole-brain atrophy rates were measured using three-dimensional T1-weighted imaging. The influence of age, sex, apolipoprotein E genotype (APOE), baseline MMSE, baseline hippocampal volume, and baseline normalized brain volume on whole-brain atrophy rates was assessed using linear regression. RESULTS: The mean whole-brain atrophy rate was -1.9 +/- 0.9% per year. In the multivariate model, younger age (beta [SE] = 0.03 [0.01]; p = 0.04), absence of APOE epsilon 4 (beta [SE] = 0.61 [0.28]; p = 0.03), and a low MMSE (beta [SE] = 0.11 [0.03]; p < 0.001) were associated with a higher whole-brain atrophy rate. Furthermore, a relatively spared hippocampus predicted faster decline for patients with a smaller baseline brain volume (p = 0.09), and with a lower MMSE (p = 0.07). Finally, a smaller brain volume was associated with a higher rate of atrophy in younger patients (p = 0.03). CONCLUSIONS: Our results suggest it is possible to characterize a subgroup of patients with Alzheimer disease (AD) who are at risk of faster loss of brain volume. Patients with more generalized, rather than focal hippocampal atrophy, who often have an onset before the age of 65, and are APOE epsilon 4 negative, seem to be at risk of faster whole-brain atrophy rates than the more commonly seen patients with AD, who are older, are APOE epsilon 4 positive, and have pronounced hippocampal atrophy.
OBJECTIVE: To assess which baseline clinical and MRI measures influence whole-brain atrophy rates, measured from serial MR imaging. METHODS: We recruited 65 patients with Alzheimer disease (mean +/- SD age 70 +/- 8 y, 58% women, Mini-Mental State Examination [MMSE] 22 +/- 5), scanned with an average interval of 1.7 +/- 0.6 years. Whole-brain atrophy rates were used as outcome measure. Baseline normalized brain volume, hippocampal volume, and whole-brain atrophy rates were measured using three-dimensional T1-weighted imaging. The influence of age, sex, apolipoprotein E genotype (APOE), baseline MMSE, baseline hippocampal volume, and baseline normalized brain volume on whole-brain atrophy rates was assessed using linear regression. RESULTS: The mean whole-brain atrophy rate was -1.9 +/- 0.9% per year. In the multivariate model, younger age (beta [SE] = 0.03 [0.01]; p = 0.04), absence of APOE epsilon 4 (beta [SE] = 0.61 [0.28]; p = 0.03), and a low MMSE (beta [SE] = 0.11 [0.03]; p < 0.001) were associated with a higher whole-brain atrophy rate. Furthermore, a relatively spared hippocampus predicted faster decline for patients with a smaller baseline brain volume (p = 0.09), and with a lower MMSE (p = 0.07). Finally, a smaller brain volume was associated with a higher rate of atrophy in younger patients (p = 0.03). CONCLUSIONS: Our results suggest it is possible to characterize a subgroup of patients with Alzheimer disease (AD) who are at risk of faster loss of brain volume. Patients with more generalized, rather than focal hippocampal atrophy, who often have an onset before the age of 65, and are APOE epsilon 4 negative, seem to be at risk of faster whole-brain atrophy rates than the more commonly seen patients with AD, who are older, are APOE epsilon 4 positive, and have pronounced hippocampal atrophy.
Authors: Shannon L Risacher; Li Shen; John D West; Sungeun Kim; Brenna C McDonald; Laurel A Beckett; Danielle J Harvey; Clifford R Jack; Michael W Weiner; Andrew J Saykin Journal: Neurobiol Aging Date: 2010-08 Impact factor: 4.673
Authors: Giovanni B Frisoni; Nick C Fox; Clifford R Jack; Philip Scheltens; Paul M Thompson Journal: Nat Rev Neurol Date: 2010-02 Impact factor: 42.937
Authors: Xingbin Wang; Oscar L Lopez; Robert A Sweet; James T Becker; Steven T DeKosky; Mahmud M Barmada; F Yesim Demirci; M Ilyas Kamboh Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Duygu Tosun; Norbert Schuff; Diana Truran-Sacrey; Leslie M Shaw; John Q Trojanowski; Paul Aisen; Ronald Peterson; Michael W Weiner Journal: Neurobiol Aging Date: 2010-06-08 Impact factor: 4.673
Authors: Christiane Möller; Wiesje M van der Flier; Adriaan Versteeg; Marije R Benedictus; Mike P Wattjes; Esther L G M Koedam; Philip Scheltens; Frederik Barkhof; Hugo Vrenken Journal: Eur Radiol Date: 2013-10-04 Impact factor: 5.315
Authors: M Pievani; P E Rasser; S Galluzzi; L Benussi; R Ghidoni; F Sabattoli; M Bonetti; G Binetti; P M Thompson; G B Frisoni Journal: Neuroimage Date: 2009-01-21 Impact factor: 6.556